These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9473866)

  • 1. Treatment of type 2 diabetes: a review of metformin in clinical practice.
    Hadley RD; Whaley JW; Askins DG
    J S C Med Assoc; 1998 Jan; 94(1):12-5. PubMed ID: 9473866
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring safety and effectiveness in patients receiving metformin.
    Choe HM; Cornish L; Townsend K; Jobe J; Mitrovich S
    Am J Health Syst Pharm; 2004 Aug; 61(15):1550-1. PubMed ID: 15372824
    [No Abstract]   [Full Text] [Related]  

  • 3. How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea?
    Bell DS; Ovalle F
    Endocr Pract; 2000; 6(4):293-5. PubMed ID: 11242605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS; Hershon PM
    Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes.
    Vos RC; Rutten GEHM
    JAMA; 2017 Oct; 318(15):1489-1490. PubMed ID: 29049639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tough glucose reduction necessary in newly diagnosed diabetes].
    Rydén M
    Lakartidningen; 2010 Nov 10-16; 107(45):2810-4. PubMed ID: 21179867
    [No Abstract]   [Full Text] [Related]  

  • 8. Triple oral anti-diabetic therapy in type 2 diabetes.
    Barnett AH
    Diabet Med; 2003 Jan; 20 Suppl 1():14-6. PubMed ID: 12647835
    [No Abstract]   [Full Text] [Related]  

  • 9. Glycemic durability of monotherapy for diabetes.
    Rathmann W; Kostev K; Haastert B
    N Engl J Med; 2007 Mar; 356(13):1378-9; author reply 1380. PubMed ID: 17392313
    [No Abstract]   [Full Text] [Related]  

  • 10. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor.
    Riddle MC
    Diabetes Care; 2008 Feb; 31 Suppl 2():S125-30. PubMed ID: 18227472
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined insulin and sulfonylurea therapy for type 2 diabetes mellitus.
    Riddle MC
    Diabetes Res Clin Pract; 1991 Jan; 11(1):3-8. PubMed ID: 2019232
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study.
    Hsia SH; Duran P; Lee ML; Davidson MB
    J Diabetes; 2020 Jan; 12(1):91-94. PubMed ID: 31574564
    [No Abstract]   [Full Text] [Related]  

  • 14. A summary of the ADVANCE Trial.
    Heller SR;
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S357-61. PubMed ID: 19875581
    [No Abstract]   [Full Text] [Related]  

  • 15. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
    Kiayias JA; Vlachou ED; Theodosopoulou E; Lakka-Papadodima E
    Diabetes Care; 2002 Jul; 25(7):1251-2. PubMed ID: 12087036
    [No Abstract]   [Full Text] [Related]  

  • 16. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea.
    Barnett AH; Dreyer M; Lange P; Serdarevic-Pehar M
    Diabetes Care; 2006 Jun; 29(6):1282-7. PubMed ID: 16732009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy.
    Herman WH; Buse JB; Arakaki RF; Dungan KM; Jiang HH; Jacobson JG; Fahrbach JL
    Endocr Pract; 2011; 17(4):563-7. PubMed ID: 21550959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.
    Diabetes Care; 1998 Jan; 21(1):87-92. PubMed ID: 9538975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy.
    Yu HM; Kim SJ; Chun SW; Park KY; Lim DM; Lee JM; Hong JH; Park KS
    Diabetes Res Clin Pract; 2019 Sep; 155():107796. PubMed ID: 31326458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P; Sugimoto D; Vlajnic A; Kilo C
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.